Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells
Hsueh‐Chou Lai(China Medical University), Wen‐Lung Ma(Asia University), Pei-Ying Liao(China Medical University), Wei-Chun Cheng(China Medical University), Fu-Ju Lei(China Medical University), Long‐Bin Jeng(National Cancer Center), Cheng-Lung Hsu(Chang Gung University), Chun-Chieh Yeh(China Medical University), Xiujun Cai(National Instruments (Ireland)), Shang-Fen Huang(China Medical University), Chawnshang Chang(China Medical University)
Cited by 22
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Induction of the TRPM-2 gene in cells undergoing programmed death.
|Molecular and Cellular Biology|1989|463
Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular Carcinoma
|Gastroenterology|2008|253